Publication

Highly effective adoptive t cell therapy

Li Tang, Yugang Guo, Bing Feng
2023
Patents

Abstract

The present invention relates generally to the field of anti-cancer therapy and autoimmune therapy, in particular to the use of adoptive T cell transfer therapy. More specifically, the present invention relates to compositions, pharmaceutical compositions or methods using IL-4, a fragment or variant thereof, fused to a moiety, to increase the efficacy of an anti-cancer immunotherapy or an autoimmune therapy.

Official source

https://infoscience.epfl.ch/entities/publication/5dc44ced-d7f5-486d-9406-4aafed513633

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Highly effective adoptive t cell therapy

Chat with Graph Search

Multivalent Presentation of TCRs on DNA Nanostructures as a Sensitive Probe for pMHC Detection

PSMA-Targeted Small Molecule–Drug Conjugates Based on a Postprolyl Peptidase–Cleavable Linker for the Treatment of Prostate Cancer

Exploration and modulation of mechanical cues for enhanced cancer immunotherapy